Binzotim 1%+0.5% (Ophthalmic Suspension)

Indications

• Decrease of intraocular pressure (IOP) in patients with open-angle glaucoma
• Decrease of intraocular pressure (IOP) in patients with ocular hypertension

Pharmacology

• Potent inhibitor of human carbonic anhydrase II (CA-II)
• Inhibition of CA-II in the ciliary processes of the eye decreases aqueous humour secretion
• Non-selective beta-adrenergic blocking agent
• No intrinsic sympathomimetic, direct myocardial depressant or membrane-stabilising activity

Dosage & Administration

• Recommended dosage is one drop in the conjunctival sac of the affected eye(s) twice daily

Interaction

• Interacts with ketoconazole, itraconazole, clotrimazole, ritonavir, troleandromycin
• Interacts with oral Ca-channel blockers, guanethidine, β-blockers, antiarrhythmics, digitalis glycosides, parasympathomimetics
• Interacts with quinidine, cimetidine

Contraindications

• History of hypersensitivity to Brinzolamide and other Sulphonamides
• History of hypersensitivity to Timolol
• History of hypersensitivity to any other component of the medication

Side Effects

• Blurred vision
• Eye pain
• Eye irritation
• Foreign body sensation in eyes

Pregnancy & Lactation

• Pregnancy Category C
• Limited data on use of Brinzolamide in pregnant women
• Reproductive toxicity shown in animal studies
• No adverse effects of Timolol in eye drops on pregnancy or foetus health
• Uncertain excretion of Brinzolamide in human breast milk
• Excretion of Brinzolamide in breast milk shown in animal studies
• Timolol excretion in human breast milk
• No anticipated effects on breastfed infants at therapeutic doses of brinzolamide and Timolol ophthalmic suspension

Precautions & Warnings

• Acid-base disturbances reported with oral carbonic anhydrase inhibitors
• Discontinue use if signs of serious reactions or hypersensitivity occur
• Cardiovascular and pulmonary adverse reactions may occur with the beta-adrenergic component, Timolol
• Cardiac failure should be adequately controlled before beginning therapy with Timolol
• Patients with a history of severe cardiac disease should be monitored for signs of cardiac failure
• Pulse rates should be checked in patients with a history of severe cardiac disease

Therapeutic Class

• Drugs for miotics and glaucoma

Storage Conditions

• Do not store above 30°C temperature
• Keep away from light and wet place
• Keep out of reach of children
• To prevent contamination, do not touch the dropper tip with eyelids or other surfaces
• Tightly close the bottle when not in use
• Do not use after 4 weeks of first opening

Related Brands

• Genazopt T 1%+0.5% (Ophthalmic Suspension) - general-pharmaceuticals-ltd